Department of Parasitology, College of Veterinary Medicine, Sichuan Agricultural University, Ya'an, China.
DNA Cell Biol. 2012 Jul;31(7):1174-81. doi: 10.1089/dna.2011.1395. Epub 2012 Feb 17.
The Baylisascaris schroederi infection rate among wild giant pandas may reach over 50% or even 100%, making it one of the leading causes of death from primary or secondary infection in wild populations. Until now, little was known about how protective immunity to B. schroederi infection could be achieved. The present study was conducted to evaluate the immunogenicity and protective efficacy of recombinant Bs-Ag1 from B. schroederi, by cloning the full-length Bs-Ag1 gene of B. schroederi and expressing it in a heterologous host, Escherichia coli BL21. In mice vaccinated with rBs-Ag1 coupled with Freund's complete adjuvant (FCA), there was a significant reduction (69.2%) in the recovery of challenged B. schroederi L3 compared with either nonvaccinated controls or mice vaccinated with FCA alone. Our study supports the use of Bs-Ag1 as a potential candidate for vaccination against B. schroederi infection and provides basic data for further vaccination trials with mixtures of antigens (with Bs-Ag2 and Bs-Ag3) to B. schroederi.
感染贝氏蛔虫的野生大熊猫感染率可能超过 50%,甚至 100%,这使其成为野生种群中原发性或继发性感染的主要死亡原因之一。到目前为止,人们对如何获得针对贝氏蛔虫感染的保护性免疫知之甚少。本研究通过克隆贝氏蛔虫全长 Bs-Ag1 基因并在异源宿主大肠杆菌 BL21 中表达,评估了重组 Bs-Ag1 的免疫原性和保护效力。在与福氏完全佐剂 (FCA) 一起接种 rBs-Ag1 的小鼠中,与未接种对照或单独接种 FCA 的小鼠相比,受挑战的贝氏蛔虫 L3 的恢复量显著减少 (69.2%)。我们的研究支持将 Bs-Ag1 用作抗贝氏蛔虫感染疫苗的潜在候选物,并为进一步用抗原混合物(与 Bs-Ag2 和 Bs-Ag3 混合)进行贝氏蛔虫的疫苗接种试验提供了基础数据。